Orforglipron hemicalcium hydrate |
| Catalog No.GC70336 |
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 3008544-96-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Orforglipron hemicalcium hydrate (0.94-4.8 nM in plasma concentration, i.v., or 0.05-0.1 mg/mL, i.g. for 5 days) suppresses food intake in a dose-dependent manner, promotes insulin secretion and blood glucose reduction in cynomolgus monkey model[1].
Orforglipron hemicalcium hydrate (0.05-1.35 mg/kg, i.g.) reaches Cmax 2 hours after administration at all doses, exhibits proportional ratio of increase in plasma drug exposure to dose increase, indicates a dose-dependent absorption in the gastrointestinal tract[1].
Pharmacokinetic Analysis of Orforglipron hemicalcium hydrate in cynomolgus monkey [1]
| route | Dose (mg/kg) | Tmax (h) | Cmax (ng/mL) | AUC0-24h (ng·h/mL) |
| i.g. | 0.05 | 2.0 | 4.78 | 23.7 |
| i.g. | 0.15 | 2.0 | 20.7 | 135 |
| i.g. | 0.45 | 2.0 | 32.0 | 208 |
| i.g. | 1.35 | 2.0 | 148 | 1040 |
References:
[1]. Pyrazolopyridine derivative having glp-1 receptor agonist effect. WO2018056453A1
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *